{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Cycle 1 Day 1, n=5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2225.57","value":"3761.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 2 Day 1, n=4"},{"categories":[{"measurements":[{"comment":"NA indicates that standard deviation could not be calculated for a single participant.","groupId":"OG000","spread":"NA","value":"8401.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Cycle 3 Day 1, n=1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days).","id":"OG000","title":"Part 2: GSK2857916 3.40 mg/kg (NHL)"}],"paramType":"MEAN","populationDescription":"Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).","reportingStatus":"POSTED","timeFrame":"Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 3)","title":"Ctrough of GSK2857916 Following IV Dose in Participants With NHL-Part 2","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter"}